Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neoplasms × TAS-116 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

pembrolizumab 66 Paclitaxel 56 Gemcitabine 50 Carboplatin 50 Cisplatin 39 Docetaxel 36 Bevacizumab 33 Nivolumab 28 Irinotecan 25 Pemetrexed 24 Cyclophosphamide 24 Fluorouracil 23 Capecitabine 22 Erlotinib Hydrochloride 20 venetoclax 19 Cetuximab 19 trametinib 17 Leucovorin 16 Topotecan 15 Afatinib 15 fludarabine 14 Radiotherapy 14 130-nm albumin-bound paclitaxel 14 regorafenib 13 budigalimab 13 Sorafenib 13 Oxaliplatin 13 atezolizumab 12 Doxorubicin 12 Dexamethasone 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02965885 2024-09-04

A Study of TAS-116 in Patients With Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡